Xingimaging Opens State-Of-The-Art Research Facility In New Haven, Connecticut
"We are proud to open this facility in the City of New Haven, a hub for research and healthcare innovation," said Gilles Tamagnan, CEO of XingImaging. "The new facility represents a significant leap forward in our mission to deliver high-quality imaging solutions and accelerate the development of life-saving treatments. Our commitment to quality is reflected in every aspect of our research, from the radiotracer manufacturing process to the meticulous analysis of clinical imaging data. Our focus on scientific innovation is exemplified by the inclusion of the state-of-the-art NeuroExplorer
PET camera."
The NeuroExplorer PET camera from United Imaging is the world's first ultra-high-performance brain PET scanner offering unparalleled resolution (1.4 mm FWHM) and sensitivity (46 kcps/MBq) in the study of brain function. This promises to be a true game changer for imaging of neurodegenerative diseases, like Parkinson's & Alzheimer's, and psychiatric diseases enabling high signal to noise imaging even for small brain structures.
The integration of the NeuroExplorer PET camera into XingImaging's services further enhances the company's ability to deliver the highest quality science for its research and drug development partners.
Our New Haven facility will offer a comprehensive range of services, including:
Clinical Trial Services: State-of-the-art Clinic providing consistent, compassionate, and high-quality services to research participants to support clinical trials.
Advanced Imaging Services: Advanced imaging technologies, designed and implemented with an emphasis on precision and quality, including
PET and SPECT.
Radiotracer Manufacturing: Tailored GMP production to meet the precise needs of clinical trials with stringent quality control.
Leading Imaging Analysis Services: Tailored analysis pipelines that focus on maximizing signal-to-noise, robustness and reproducibility.
XingImaging's commitment to excellence is reflected in every aspect of the new facility's operations, ensuring that participants, sponsors, and collaborators receive the highest quality of service.
For more information about XingImaging and its services, please visit or contact us at [email protected] .
About XingImaging
XingImaging, a subsidiary of MITRO, is a leading provider of advanced research imaging and radiopharmaceutical services. With a firm focus on quality and innovation, the company offers comprehensive clinical trial imaging services, core lab services, and radiotracer manufacturing. By maintaining the highest industry standards, XingImaging partners with research pharmaceutical, and biotech organizations to drive breakthroughs in medical diagnostics and treatment.
About MITRO
MITRO is a molecular imaging contract research organization (MI-CRO) company in
China. MITRO provides outstanding contract research for new drug development using radiolabeling and molecular imaging techniques. MITRO merged with XingImaging in 2023 to create one company dedicated to providing a full spectrum of CRO & CDMO research service offerings.
SOURCE XingImaging, LLC
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Manuka Honey Market Report 2024, Industry Growth, Size, Share, Top Compan...
- Modular Kitchen Market 2024, Industry Growth, Share, Size, Key Players An...
- Acrylamide Production Cost Analysis Report: A Comprehensive Assessment Of...
- Fish Sauce Market 2024, Industry Trends, Growth, Demand And Analysis Repo...
- Australia Foreign Exchange Market Size, Growth, Industry Demand And Forec...
- Cold Pressed Oil Market Trends 2024, Leading Companies Share, Size And Fo...
- Pasta Sauce Market 2024, Industry Growth, Share, Size, Key Players Analys...
Comments
No comment